v3.25.2
Condensed Consolidated Statements of Cash Flows
$ in Thousands
 6 Months Ended
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Cash flows from operating activities:      
Net income (loss) $ 5,117 $ (48,053)  
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:      
Depreciation and amortization 660 626  
Inventory obsolescence 1,026 1  
Stock-based compensation expense 42,672 26,825  
Payment of Pharmakon PIK Interest (5,492) 0  
Non-cash interest expense on royalty financing obligations 26,916 28,450  
Non-cash interest expense on secured term loan and amortization of debt issuance costs 1,003 10,591  
Amortization of discount on investments, net (2,533) (6,674)  
Loss on extinguishment of debt 4,171 0  
Changes in operating assets and liabilities:      
Increase in receivables (21,295) (12,085)  
Decrease (increase) in inventory 568 (481)  
Decrease in prepaid expenses and other assets 28 2,851  
Decrease in royalty financing obligations (36,921) (33,069)  
Decrease in accounts payable and accrued expenses (2,135) (24,034)  
Net cash provided by (used in) operating activities 13,785 (55,052)  
Cash flows from investing activities:      
Acquisitions of property and equipment (322) (390)  
Purchases of investments (78,103) (200,303)  
Sales and maturities of investments 134,647 227,000  
Net cash provided by investing activities 56,222 26,307  
Cash flows from financing activities:      
Net proceeds from common stock issued under stock-based compensation plans 5,811 1,945  
Common stock issued to directors in lieu of cash retainer 15 23  
Repayment of Pharmakon term loan principal (69,508) 0  
Prepayment premium and fees on Pharmakon term loan (2,250) 0  
Principal payments on royalty financing obligations (3,956) 0  
Withholding taxes paid on stock-based awards (2,217) (4,190)  
Principal payments on finance lease liabilities (1,052) (792)  
Net cash used in financing activities (73,157) (3,014)  
Effect of exchange rates on cash, cash equivalents and restricted cash 1,810 (483)  
Net decrease in cash, and cash equivalents, and restricted cash (1,340) (32,242)  
Less: net increase in cash and cash equivalents classified within current assets held for sale (15,058) 0  
Net decrease in cash, and cash equivalents, and restricted cash (16,398) (32,242)  
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation     $ 112,447
Cash, cash equivalents and restricted cash at end of period 89,925 80,205  
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]      
Cash and cash equivalents 88,033 78,410  
Restricted cash 492 1,795  
Restricted cash in other assets 1,400 0  
Total cash, cash equivalents and restricted cash 89,925 80,205  
Supplemental Cash Flow Information [Abstract]      
Cash paid for interest 16,679 10,041  
Cash paid for taxes 1,228 865  
Purchases of property and equipment included in accounts payable 1,069 0  
Taxes withheld on stock-based awards included in accrued expenses $ 343 $ 189